Drug Trial Radar · NCT05460767
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
504
Actual
Start
Aug 31, 2022
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine the recommended phase 2 dose (RP2D).
Conditions
- Solid Tumors or Lymphoma
Interventions
IBI363Biological
a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
BevacizumabDrug
Recombinant humanized monoclonal antibody against vascular endothelial growth factor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of dose-limiting toxicity (DLT)Time frame: 21 days during the first 3-week cycle
- incidence of adverse events (AE), serious adverse events (SAEs), treatment-emergent AEs (TEAEs) and immune-related AEs (irAEs)Time frame: up to 90 days after the last administration
- Number of participants with abnormality in vital signsTime frame: up to 90 days after the last administration
- Number of participants with abnormality in hematology parametersTime frame: up to 90 days after the last administration
- Number of participants with abnormality in clinical chemistry parametersTime frame: up to 90 days after the last administration
- Number of participants with abnormality in routine urinalysis parametersTime frame: up to 90 days after the last administration
- Number of participants with abnormality in ECG parametersTime frame: up to 90 days after the last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.